Egis Pharmaceuticals Plc., Keresztúri út 30-38, 1106 Budapest, Hungary.
School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet, 1, 1206 Geneva, Switzerland.
J Pharm Biomed Anal. 2020 Aug 5;187:113371. doi: 10.1016/j.jpba.2020.113371. Epub 2020 May 19.
This work was motivated by the demand of European Directorate for the Quality of Medicines and HealthCare (EDQM). A new liquid chromatographic (LC) method was developed for terazosin impurity profiling to replace the old European Pharmacopoeia (Ph. Eur.) method. This new method is published as part of the new Ph. Eur. monograph proposal of terazosin in Pharmeuropa issue 32.2. The aim of the method renewal was to cut the analysis time from 90 min (2 × 45 min) down to below 20 min. The Ph. Eur. monograph method is based on two different chromatographic separations to analyze the specified impurities of terazosin. The reason for the two methods is that two of the impurities are not sufficiently retained in reversed phase (RP) conditions, not even with 100% water as eluent. Therefore, next to RP, an ion-pair (IP) chromatographic method has to be applied to analyze those two impurities. With our new proposed method it was possible to appropriately increase the retention of the two critical compounds using alternative stationary phases (instead of a C18 phase which is suggested by the Ph. Eur. method). Applying a pentafluoro-phenyl (PFP) stationary phase, it was feasible to separate and adequately retain all the impurities. The detection wavelength was also changed compared to the Ph. Eur. method and is now appropriate for the detection and quantification of all impurities using perchloric acid in the mobile phase at low pH. Another goal of the present study was to develop a generic workflow and to evaluate the chromatographic resolution in a wide range of method variables and suggest some replacement columns for terazosin impurity profiling. Retention modeling was applied to study the chromatographic behavior of the compounds of interest and visualize resolution for the different columns, where a given criterion is fulfilled. A zone (set of chromatographic conditions) of a robust space could be then quickly identified by the overlay of the individual response surfaces (resolution maps). It was also demonstrated that two columns from different providers (Kinetex F5 and SpeedCore PFP) can be used as replacement columns, providing sufficient resolution at the same working point and a high degree of robustness.
这项工作的起因是欧洲药品质量管理局(EDQM)的需求。为了对特拉唑嗪杂质进行分析,建立了一种新的液相色谱(LC)方法,以取代旧的欧洲药典(Ph. Eur.)方法。该方法已作为欧洲药典中特拉唑嗪新专论提案的一部分在《Pharmeuropa》第 32.2 期发布。该方法更新的目的是将分析时间从 90 分钟(2×45 分钟)缩短至 20 分钟以下。Ph. Eur. 专论方法基于两种不同的色谱分离来分析指定的特拉唑嗪杂质。之所以采用两种方法,是因为其中两种杂质在反相(RP)条件下不能充分保留,即使以 100%水作为洗脱液也不行。因此,除了 RP 方法之外,还必须应用离子对(IP)色谱方法来分析这两种杂质。采用我们新提出的方法,可以通过替代固定相适当增加两种关键化合物的保留时间(而不是 Ph. Eur. 方法中建议的 C18 相)。采用五氟苯基(PFP)固定相,可实现所有杂质的分离和适当保留。与 Ph. Eur. 方法相比,检测波长也有所改变,现在可使用流动相中低 pH 值的高氯酸检测和定量所有杂质。本研究的另一个目标是开发一种通用工作流程,并在广泛的方法变量范围内评估色谱分辨率,并为特拉唑嗪杂质分析建议一些替代色谱柱。保留建模用于研究感兴趣化合物的色谱行为,并可视化不同色谱柱的分辨率,其中满足给定标准。然后可以通过叠加各个响应曲面(分辨率图)快速识别稳健空间的一个区域(一组色谱条件)。还证明了来自不同供应商的两根色谱柱(Kinetex F5 和 SpeedCore PFP)可以作为替代色谱柱使用,在相同的工作点提供足够的分辨率和高度的稳健性。